ES2380913T3 - Uso de L-carnitina para el tratamiento de enfermerdades cardiovasculares - Google Patents

Uso de L-carnitina para el tratamiento de enfermerdades cardiovasculares Download PDF

Info

Publication number
ES2380913T3
ES2380913T3 ES05755616T ES05755616T ES2380913T3 ES 2380913 T3 ES2380913 T3 ES 2380913T3 ES 05755616 T ES05755616 T ES 05755616T ES 05755616 T ES05755616 T ES 05755616T ES 2380913 T3 ES2380913 T3 ES 2380913T3
Authority
ES
Spain
Prior art keywords
carnitine
vol
acid
glucose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05755616T
Other languages
English (en)
Spanish (es)
Inventor
Aleardo Koverech
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of ES2380913T3 publication Critical patent/ES2380913T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES05755616T 2004-07-13 2005-06-21 Uso de L-carnitina para el tratamiento de enfermerdades cardiovasculares Expired - Lifetime ES2380913T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM20040346 2004-07-13
IT000346A ITRM20040346A1 (it) 2004-07-13 2004-07-13 Uso della l-carnitina per il trattamento di patologie cardiovascolari.
PCT/EP2005/006657 WO2006005415A2 (en) 2004-07-13 2005-06-21 Use of l-carnitine and glucose for the treatment of cardiovascular diseases

Publications (1)

Publication Number Publication Date
ES2380913T3 true ES2380913T3 (es) 2012-05-21

Family

ID=34971575

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05755616T Expired - Lifetime ES2380913T3 (es) 2004-07-13 2005-06-21 Uso de L-carnitina para el tratamiento de enfermerdades cardiovasculares

Country Status (21)

Country Link
US (2) US7879908B2 (https=)
EP (1) EP1773314B1 (https=)
JP (1) JP5230195B2 (https=)
KR (1) KR101296479B1 (https=)
CN (2) CN101087602B (https=)
AT (1) ATE542529T1 (https=)
AU (1) AU2005262050B2 (https=)
BR (1) BRPI0513303A8 (https=)
CA (1) CA2569888C (https=)
CY (1) CY1112686T1 (https=)
DK (1) DK1773314T3 (https=)
ES (1) ES2380913T3 (https=)
HR (1) HRP20120178T1 (https=)
IT (1) ITRM20040346A1 (https=)
ME (1) ME01345B (https=)
MX (1) MXPA06014665A (https=)
PL (1) PL1773314T3 (https=)
PT (1) PT1773314E (https=)
RS (1) RS52253B (https=)
SI (1) SI1773314T1 (https=)
WO (1) WO2006005415A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086543A1 (es) * 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1120033B (it) * 1979-10-05 1986-03-19 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale
JPS6415220A (en) 1987-07-06 1989-01-19 Mitsubishi Electric Corp Tension control device for utilizing maximum torque and maximum electric current of winding motor
JPH06102624B2 (ja) * 1990-08-10 1994-12-14 アース製薬株式会社 非心臓由来の不整脈防止薬
IT1261695B (it) * 1993-06-02 1996-05-29 Sigma Tau Ind Farmaceuti Impiego di l-carnitina e alcanoil l-carnitine nella conservazione del sangue per trasfusioni e soluzioni stabilizzatrici che le contengono.
US5998386A (en) * 1997-09-19 1999-12-07 Feldman; Arthur M. Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue
EP1133289A1 (en) * 1998-11-26 2001-09-19 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Use of fumarate salt of l-carnitine or its alkanoyl derivatives in ischaemia
JP4638106B2 (ja) 1999-10-11 2011-02-23 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ 医薬的使用のための溶液中における浸透圧剤としての、ｌ−カルニチンおよびそのアルカノイル誘導体の使用
EP1499580B1 (en) * 2002-04-01 2012-03-28 The Governors of the University of Alberta Compounds that stimulate glucose utilization and methods of use
ITRM20030178A1 (it) 2003-04-17 2004-10-18 Sigma Tau Ind Farmaceuti Uso della l-carnitina per il trattamento di patologie cardiovascolari.

Also Published As

Publication number Publication date
EP1773314A2 (en) 2007-04-18
DK1773314T3 (da) 2012-05-07
KR101296479B1 (ko) 2013-08-13
WO2006005415A2 (en) 2006-01-19
US20070207970A1 (en) 2007-09-06
WO2006005415A3 (en) 2006-05-26
PL1773314T3 (pl) 2012-06-29
CA2569888A1 (en) 2006-01-19
HK1166003A1 (zh) 2012-10-19
CA2569888C (en) 2013-08-13
SI1773314T1 (sl) 2012-04-30
RS52253B (sr) 2012-10-31
CN101087602B (zh) 2011-09-14
HRP20120178T1 (hr) 2012-05-31
ITRM20040346A1 (it) 2004-10-13
CN102349923A (zh) 2012-02-15
EP1773314B1 (en) 2012-01-25
CY1112686T1 (el) 2016-02-10
PT1773314E (pt) 2012-03-29
KR20070039541A (ko) 2007-04-12
ME01345B (me) 2012-10-31
HK1113542A1 (en) 2008-10-10
US20110086917A1 (en) 2011-04-14
AU2005262050B2 (en) 2011-02-24
BRPI0513303A (pt) 2008-05-06
MXPA06014665A (es) 2007-03-12
CN102349923B (zh) 2016-04-27
CN101087602A (zh) 2007-12-12
ATE542529T1 (de) 2012-02-15
US8394854B2 (en) 2013-03-12
BRPI0513303A8 (pt) 2017-12-26
JP5230195B2 (ja) 2013-07-10
AU2005262050A1 (en) 2006-01-19
US7879908B2 (en) 2011-02-01
JP2008517872A (ja) 2008-05-29

Similar Documents

Publication Publication Date Title
AU2010202396A1 (en) Use of L-carnitine for the treatment of cardiovascular diseases
ES2250749T3 (es) Uso de una composicion combinada que comprende propionil l-carnitina y otros farmacos para el tratamiento de la disfuncion erectil.
ES2380913T3 (es) Uso de L-carnitina para el tratamiento de enfermerdades cardiovasculares
ES2671639T3 (es) Métodos para controlar la presión arterial y reducir la disnea en la insuficiencia cardiaca
JP2006523685A5 (https=)
ES2203115T3 (es) Composicion que comprende ketanserina y l-carnitina para el tratamiento del sindrome de dolor local cronico.
US20090042983A1 (en) Use of L-carnitine for the treatment of cardiovascular diseases
JP2008517872A5 (https=)
Lorimer et al. Cardiovascular disease
HK1113542B (en) Use of l-carnitine and glucose for the treatment of cardiovascular diseases
HK1132174A (en) Use of l-carnitine for the treatment of cardiovascular diseases
HK1085929A (en) Use of l-carnitine for the treatment of cardiovascular diseases